Search results for "Side effect"

showing 10 items of 189 documents

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwid…

2016

Background: Psoriasis induced by anti-tumor necrosis factor-alpha (TNF) therapy has been described as a paradoxical side effect. Aim: To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Methods: Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes geneticos y Ambientales registry of Grupo Espanol de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with ant…

MaleAnti-Inflammatory AgentsInflammatory bowel diseaseGastroenterologyCohort Studies030207 dermatology & venereal diseases0302 clinical medicineCrohn DiseaseadalimumabImmunology and AllergyIncidence (epidemiology)IncidenceGastroenterologypsoriasisPrognosisside effectsCrohn's diseaseCohort030211 gastroenterology & hepatologyTumor necrosis factor alphaFemaleCohort studyAdultmedicine.medical_specialtyAdolescent03 medical and health sciencesGastrointestinal Agentsinflammatory bowel diseasePsoriasisInternal medicinemedicineHumansPsoriasisColitisulcerative colitisbusiness.industryTumor Necrosis Factor-alphaCase-control studyAdalimumabanti-TNFmedicine.diseaseInfliximabWithholding TreatmentSpainCase-Control StudiesPhysical therapyColitis UlcerativebusinessinfliximabFollow-Up Studies
researchProduct

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

2014

ABSTRACT:  Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. Af…

MaleCancer Researchmedicine.medical_specialtyVatalanibDrug-Related Side Effects and Adverse ReactionsPyridinesMedizinContrast MediaAngiogenesis InhibitorsStable DiseaseText miningCarcinoma Non-Small-Cell LungmedicineHumansIn patientLung cancerAgedNeoplasm StagingClinical Trials as Topicbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRadiographyOncologyResponse Evaluation Criteria in Solid TumorsDynamic contrast-enhanced MRIDrug EvaluationPhthalazinesFemaleRadiologyNuclear medicinebusinessProgressive diseaseBiomarkersFuture oncology (London, England)
researchProduct

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype…

2017

Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naive and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65.3%) were male, and the mean age was 57.5years. The mean baseline viral load was 6.1 log, 69.8% had HCV 1b genotype, 72.9% had cirrhosis and 34.7% were treatment-naive. SVR at 12 w…

MaleCirrhosisSustained Virologic ResponseHepacivirusmedicine.disease_causechemistry.chemical_compound0302 clinical medicinesevere fibrosisdasabuvirMedicineAged 80 and overMiddle AgedInfectious DiseasesTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleViral loadmedicine.drugAdultmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsGenotypeHepatitis C viruscompassionate useAntiviral Agents03 medical and health sciencesVirologyInternal medicineHumansAdverse effectAgedRetrospective StudiesHepatologybusiness.industryRibavirinparitaprevirHepatitis C Chronicmedicine.diseaseVirologydigestive system diseasesOmbitasvirDiscontinuationombitasvirchemistryParitaprevirSpainhepatitis Cbusiness
researchProduct

Pelvic exenterations for primary rectal cancer: analysis from a 10-year national prospective database

2018

Aim: to identify short-term and oncologic outcomes of pelvic exenterations (PE) for locally advanced primary rectal cancer (LAPRC) in patients included in a national prospective database. Methods: few studies report on PE in patients with LAPRC. For this study, we included PE for LAPRC performed between 2006 and 2017, as available, from the Rectal Cancer Registry of the Spanish Association of Surgeons [Asociación Española de Cirujanos (AEC)]. Primary endpoints included procedure-associated complications, 5-year local recurrence (LR), disease-free survival (DFS) and overall survival (OS). A propensity-matched comparison with patients who underwent non-exenterative surgery for low rectal canc…

MaleColorectal cancerEpidemiologymedicine.medical_treatment030230 surgerycomputer.software_genre0302 clinical medicinePostoperative ComplicationsRetrospective StudieMedicineProspective StudiesOutcomeDatabaseGastroenterologyGeneral MedicineMiddle AgedColorectal surgeryTreatment OutcomeEfectes secundaris dels medicaments030220 oncology & carcinogenesisFemaleHumanAdvanced rectal cancermedicine.medical_specialtyRisk AssessmentDisease-Free SurvivalPelvis03 medical and health sciencesColorectal surgeryCàncer colorectalAdvanced rectal cancer Colorectal surgery Complication Outcome Pelvic exenterationRetrospective Cohort StudyHumansPerioperative PeriodEpidemiologiaAgedNeoplasm StagingRetrospective StudiesRectal NeoplasmPelvic exenterationbusiness.industryRectal NeoplasmsRectummedicine.diseaseColorectal cancerPelvic Exenterationbody regionsProspective StudieQuality of LifeDrug side effectsPostoperative ComplicationPelvic exenterationNeoplasm Recurrence LocalbusinessComplicationComplicationcomputer
researchProduct

[Gadolinium-containing contrast agents: Gadoterat-meglumine is safe in patients with chronic renal failure].

2014

Objective To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients. Methods Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at −15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between base…

MaleDrug-Related Side Effects and Adverse ReactionsContrast MediaAcute Kidney InjuryMeglumine gadoterateMagnetic Resonance ImagingNephrogenic Fibrosing DermopathyHeterocyclic CompoundsGd-DOTANephrogenic systemic fibrosisOrganometallic CompoundsHumansFemaleRenal Insufficiency ChronicGadolinium-based contrast agent-induced nephropathyMRIRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

When symptoms become side effects: Development of the side effect attribution scale (SEAS)

2021

Objectives\ud \ud Symptom misattribution is a central process in the nocebo effect but it is not accurately assessed in current side effect measures. We have developed a new measure, the Side Effect Attribution Scale (SEAS), which examines the degree to which people believe their symptoms are treatment side effects.\ud \ud \ud \ud Methods\ud \ud The SEAS was tested in three New Zealand studies: a vaccination sample (n = 225), patients with gout or rheumatoid arthritis (n = 102), and patients switching to a generic medicine (n = 69). The internal reliability of the scale was examined using Cronbach's alpha. To assess validity, the Side Effect Attribution Total Score and Side Effect Attributi…

MaleDrug-Related Side Effects and Adverse ReactionsSide effectNocebomedia_common.quotation_subject03 medical and health sciences0302 clinical medicineCronbach's alphaSurveys and QuestionnairesHumansMedicineMisattribution of memory030212 general & internal medicinemedia_commonbusiness.industryReproducibility of ResultsNocebo EffectPsychiatry and Mental healthClinical PsychologyScale (social sciences)FemaleWorrybusinessAttribution030217 neurology & neurosurgeryClinical psychologyJournal of Psychosomatic Research
researchProduct

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

2019

Aim: To evaluate the changes in renal endpoints in type 2 diabetes patients treated with dapagliflozin versus other glucose-lowering medications in routine clinical practice. Materials and Methods: DARWIN-T2D was a retrospective study conducted at 46 outpatient diabetes clinics in Italy. An automated software collected data on 17 285 patients who received dapagliflozin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or gliclazide, 6751 of whom had a follow-up visit. We analysed changes in albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR). Results: Patients who received dapagliflozin (n = 473) were younger, more obese, and had a poore…

MaleEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologyKidneychemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesRetrospective StudieInterquartile rangeMedicineGliclazideDiabetic NephropathiesDapagliflozinPractice Patterns Physicians'Benzhydryl CompoundAged 80 and overdatabase researchMiddle AgedDiabetes and MetabolismTreatment OutcomeItalyFemaleOriginal Articletype 2 diabetesHumanmedicine.drugGlomerular Filtration Ratemedicine.medical_specialtyGlucosideDrug-Related Side Effects and Adverse ReactionsUrologyRenal function030209 endocrinology & metabolism03 medical and health sciencesDiabetes mellitusantidiabetic drug; dapagliflozin; database research; diabetic nephropathy; type 2 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyInternal MedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective Studiesantidiabetic drugtype 2 diabeteCreatinineHypoglycemic Agentbusiness.industrydiabetic nephropathyRetrospective cohort studyBiomarkerOriginal Articlesdapagliflozinmedicine.diseasechemistryDiabetes Mellitus Type 2Diabetic NephropathieDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersDiabetes, obesitymetabolism
researchProduct

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spa…

2013

Abstract Background Given the concurrent administration of multiple vaccines during routine pediatric immunizations, efforts to elucidate the potential interference of any vaccine on the immune response to the concomitantly administered antigens are fundamental to prelicensure clinical research. Methods This phase 3 randomized controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) versus 7-valent PCV (PCV7) assessed immune responses of concomitantly administered meningococcal group C conjugated to diphtheria toxin cross-reactive material 197 (MnCCV-CRM 197 ) in a 2-dose infant series and 15-month toddler dose. Results 619 subjects were randomized, 315 to PCV13 and 304 to PCV7.…

MaleHeptavalent Pneumococcal Conjugate VaccineMeasles-Mumps-Rubella VaccineDrug-Related Side Effects and Adverse ReactionsMeningococcal VaccinesPneumococcal conjugate vaccinePneumococcal VaccinesConjugate vaccineMedicineHumansToddlerImmunization ScheduleGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityVaccinationPublic Health Environmental and Occupational HealthAntibody titerInfantAntibodies BacterialHealthy VolunteersTiterInfectious DiseasesTolerabilitySpainImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct

Medical treatment and medical side effects in urinary incontinence in the elderly

1998

MaleNephrologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsIncontinencia urinariaUrinary Incontinence StressUrologyUrinary BladderUrinary incontinenceCentral nervous system diseaseInternal medicinemedicineHumansProstatismProstate diseaseAgedMedical treatmentbusiness.industryAge FactorsMuscle Smoothmedicine.diseaseSurgeryUrinary IncontinencePhysical therapyFemalemedicine.symptombusinessWorld Journal of Urology
researchProduct

A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs

2021

We present a generic workflow combining physiology-based computational modeling and in vitro data to assess the clinical cholestatic risk of different drugs systematically. Changes in expression levels of genes involved in the enterohepatic circulation of bile acids were obtained from an in vitro assay mimicking 14 days of repeated drug administration for 10 marketed drugs. These changes in gene expression over time were contextualized in a physiology-based bile acid model of glycochenodeoxycholic acid. The simulated drug-induced response in bile acid concentrations was then scaled with the applied drug doses to calculate the cholestatic potential for each compound. A ranking of the cholest…

MalePHARMACOKINETICSAZATHIOPRINEAzathioprineBioinformatics030226 pharmacology & pharmacyWorkflowchemistry.chemical_compound0302 clinical medicinePARACETAMOLPharmacology (medical)Enterohepatic circulationmedia_common0303 health sciencesCholestasisBile acidMiddle Aged3. Good healthBenchmarkingLiverPharmaceutical PreparationsSINGLEDrug developmentFemaleVALPROATEmedicine.drugAdultDrugDrug-Related Side Effects and Adverse ReactionsDICLOFENAC SODIUMmedicine.drug_classmedia_common.quotation_subjectModels BiologicalYoung Adult03 medical and health sciencesCholestasisPharmacokineticsSpheroids CellularmedicineGlycochenodeoxycholic acidAnimalsHumansddc:610030304 developmental biologyPharmacologybusiness.industrymedicine.diseasechemistryACETAMINOPHENbusinessClinical Pharmacology & Therapeutics
researchProduct